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Abstract
Background: Gastric ulcers are a frequent problem in the United States. Proton pump inhibitors
have been shown to increase healing rates and improve clinical symptoms. The objective of this
study is to compare gastric ulcer healing rates for patients treated with a proton pump inhibitor
(PPI) (omeprazole, rabeprazole, pantoprazole, or lansoprazole), an histamine 2- receptor
antagonist (ranitidine) or placebo.
Methods: A literature search was conducted to identify randomized, controlled clinical trials that
included a PPI in at least one treatment arm and assessed the gastric ulcer healing rates
endoscopically. The healing rates were estimated for each treatment at specific time points, and
Rate Ratios (RR) and 95% confidence intervals (CI) were estimated for each trial.
Results: Sixteen trials met the inclusion criteria: four compared a PPI versus placebo, nine
compared a PPI versus ranitidine (no trials of rabeprazole versus ranitidine met the inclusion
criteria), and three compared a newer PPI (lansoprazole, pantoprazole or rabeprazole) versus
omeprazole. In relation to ranitidine, the pooled RR of PPIs (lansoprazole, omeprazole and
pantoprazole) was 1.33 (95% CI 1.24 to 1.42) at four weeks. In each trial, greater improvement in
the studied clinical symptoms was found with the newer PPIs (rabeprazole, pantoprazole and
lansoprazole) when compared to omeprazole.
Conclusion: In this study treatment with PPIs resulted in higher healing rates than ranitidine or
placebo. This evidence suggests that the first choice for gastric ulcer treatment for the greater relief
of symptoms is one of the newer PPIs.
Background
In the United States about four million people have active
peptic ulcers and about 350,000 new cases are diagnosed
each year, and approximately 3000 deaths per year in the
U.S. are due to gastric ulcer [1]. The primary therapeutic
approach to gastric ulcer remains the inhibition of gastric
acid secretion to produce symptom relief, acceleration of
crater healing and the prevention of relapse or recurrence
[2,3], since gastric ulcer can lead to hemorrhage, perfora-
tion, obstruction and death [4,5].
It is established that the H+, K+-ATPase, or proton pump,
participates in the final step of acid secretion [6,7] and all
the peripheral parietal cell stimuli converge to activate it
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[7]. Therefore, blocking the final process in hydrogen ion
secretion reduces acid secretion and this is the mechanism
of action of the substituted benzimidazole agents known
as proton pump inhibitors (PPI). Currently, five PPIs are
marketed: rabeprazole, omeprazole, esomeprazole, lanso-
prazole and pantoprazole, each with a different pharma-
cokinetic profile, tissue selectivity, binding specificity and
potential to interact with the cytochrome P450 enzyme
system [8–10]. For example, rabeprazole and esomepra-
zole achieve more rapid and profound inhibition of acid
secretion than do older agents [10]. It is unclear, however,
if these pharmacologic differences lead to distinctions in
the clinical efficacy of healing gastric ulcers and control-
ling ulcer symptoms. To address this question we under-
took a meta-analysis of all randomized clinical trials that
compared at least one of the newer PPI with either raniti-
dine or placebo.
Methods
To identify studies for inclusion in this meta-analysis, two
researchers independently conducted searches of
MEDLINE®, Cochrane Library documents. The keywords
used for these searches were: proton pump inhibitors, PPI,
rabeprazole, omeprazole, esomeprazole, lansoprazole, panto-
prazole, ranitidine; healing rates, gastric ulcer, stomach ulcer,
gastric ulcer disease, peptic ulcer, peptic related disorders; and
clinical trials, randomized clinical trials and multicenter stud-
ies. Hand searching of medical journals was carried out as
well as review of reference lists of other meta-analyses,
monographs, pharmacoeconomic studies and reviews.
The search included papers published between January
1990 to July 2001, with no language limitations.
The two researchers independently reviewed the papers
and selected all those described as randomized controlled
clinical trials, double blind, short-term treatment (less
than six months) in patients with endoscopically con-
firmed diagnosis of gastric ulcer that also included at least
one group treated with a PPI. If a paper did not report
healing rates, but reported improvement in clinical symp-
toms, this could be included for the analyses of symp-
toms.
The decision regarding whether to include a paper was not
related to trial results. Papers related to chemical proper-
ties of PPI, pharmacokinetic, pharmacodynamic, acidity
studies, concomitant duodenal ulcers or gastric ulcers
complicated with hemorrhage or perforation, PPI com-
bined with antibiotics or with treatment of Helicobacter
pylori were excluded. Papers or abstracts with insufficient
data, preliminary results, duplicate reports of the same tri-
als or with more complete reporting in another paper
were also excluded. The two researchers reviewed the stud-
ies independently and any differences in the data retrieved
from the papers were resolved by consensus. The informa-
tion entered into a database included: study design, pop-
ulation characteristics, diagnosis, severity, PPI and
comparator treatment regimens, healing rates and clinical
symptoms as well as alcohol consumption, smoking and
caffeine use.
Ulcer diagnosis and healing had to be assessed by endos-
copy; we accepted the primary study authors' definition
for gastric ulcer diagnosis and healing.
Results were retrieved for both intention to treat and per
protocol analysis, if the paper provided such data. If the
authors reported per protocol results only and mentioned
the initial number of subjects in the study, we estimated
the healing rates for the intention to treat analysis.
Statistical analysis
The healing rate ratio (RR) was calculated for each trial by
dividing the healing rate of the PPI by the rate with the
comparator at the specified time point. Chi-squares and
95% confidence intervals (CI) were calculated using the
exact method described by Miettinen [11].
The appropriateness of combining results from individual
studies was examined using the Wald χ 2 for statistical ho-
mogeneity. We considered a p value less than 0.05 to be
significant for all statistical tests. There were no adjust-
ments for multiple comparisons.
As there was no statistically significant evidence of hetero-
geneity, the healing rates for each treatment were pooled
across trials by time point. Overall healing rates of PPIs at
four and eight weeks were estimated by pooling the rates
for the recommended daily doses: 30 mg/d for lansopra-
zole, 20 mg/d for omeprazole, 40 mg/d for pantoprazole.
Rabeprazole was pooled using dose of 20 mg/d at three
and six weeks. Individual trial results were weighted using
the inverse of the variance of the RR estimated for each tri-
al. The overall RR was then estimated by dividing the
weighted average healing rates for each treatment with the
estimates for placebo, ranitidine or omeprazole. These
overall RR were assessed using the Mantel-Haenszel χ 2
test and 95% CI were calculated using the exact method
[11].
To assess the possibility of publication bias, the RR point
estimates were plotted against year of publication and
sample size. To identify any studies that exerted a dispro-
portionate influence on the summary treatment effect, we
deleted individual studies one at a time. To investigate the
possible consequences of including abstracts for which we
could not obtain full reports, we excluded these data in
secondary analyses.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/17
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Results
There were more than one thousand papers on PPI, of
which 153 focused on PPI use for the treatment of gastric
ulcers. Sixteen trials met all the criteria for inclusion (Ta-
ble 1) [12–27]. Four trials compared a PPI versus placebo
nine compared PPI versus ranitidine (no trials of rabepra-
zole versus ranitidine met the inclusion criteria), and
three compared a newer PPI (lansoprazole, pantoprazole
or rabeprazole) versus omeprazole. Omeprazole was
studied most often (6), followed by lansoprazole (4), rab-
eprazole (3) and pantoprazole (3). No study on esome-
prazole for the treatment of gastric ulcer met the inclusion
criteria.
The criteria for diagnosis of gastric ulcer varied: 57% of the
studies required the ulcer size to be 5 to 20 mm and 43%
required 3 to 25 mm. The majority (95%) defined healing
as the complete re-epithelialization of ulcer crater. The
other researchers defined healing, as the endoscopic dis-
appearance of ulcer crater with no visible mucosa breaks.
Efficacy results were reported at various time points, rang-
ing from 2 to 8 weeks.
The mean age of the patients in these trials was 56 ± 1.5
years. Approximately half the patients smoked but few
studies analyzed the healing rates by smoking status.
About half the studies reported on alcohol consumption,
and 46% of patients reported alcohol consumption at the
baseline visit. Caffeine use was infrequently reported.
Clinical symptoms
It was not possible to pool these results because different
symptoms were reported in each study, at different time
points, and also the method used to collect data varied
(Table 2). However, individual trials showed more im-
provement or resolution of pain, day pain and night pain
was found with the new PPIs rabeprazole, pantoprazole
and lansoprazole compared to omeprazole. For example,
82% of patients with pain improved with rabeprazole
compared to 65% with omeprazole at 6 weeks [26] (Table
2).
Healing rates
Healing data are presented for the intention-to-treat anal-
yses as similar results were obtained with the per protocol
analysis. For lansoprazole, pantoprazole and omeprazole
the results were reported at four and eight weeks and the
rabeprazole studies did so at three and six weeks. There-
fore, the overall healing rate was obtained at three, four,
six and eight weeks.
Healing rates varied between the studies, but were consist-
ently lower with placebo treatment. For the majority of
patients receiving placebo treatment the ulcer did not heal
during the course of the trial and the maximum recorded
as healed was just over a third of the patients (39%) in any
of the trials. Whilst higher healing rates were observed af-
ter treatment with ranitidine by the end of the trials the ul-
Table 1: Description of gastric ulcer studies by drug, sample size and dosage. Ital Coop Grp: Italian Cooperative Group, Coop St Group: 
Cooperative Study Group.
Author Study Drug Dose (mg/
d)
NC o m p a r a t o r D o s e  ( m g /
d)
N
Florent [24] Lansoprazole 30 60 Omeprazole 20 66
Witzel [25] Pantoprazole 40 163 Omeprazole 20 80
Dekkers [26] Rabeprazole 20 113 Omeprazole 20 114
Avner [12] Lansoprazole 15 68 Placebo 67
30 67
60 63
Valenzuela [13] Omeprazole 20 40 202 214 Placebo 104
Cloud [14] Rabeprazole 20 40 32 31 Placebo 31
Humphries [27] Rabeprazole 20 40 32 31 Placebo 31
Bardhan [15] Lansoprazole 30 60 82 85 Ranitidine 300 83
Michel [16] Lansoprazole 30 79 Ranitidine 300 79
Classen [17] Omeprazole 20 83 Ranitidine 300 74
Coop St Group [18] Omeprazole 40 21 Ranitidine 300 25
Ital Coop Grp [19] Omeprazole 20 84 Ranitidine 300 83
Walan [20] Omeprazole 20 40 203 194 Ranitidine 300 205
Choi [21] Omeprazole 20 125 Ranitidine 300 125
Bader [22] Pantoprazole 40 192 Ranitidine 300 123
Hotz [23] Pantoprazole 40 166 Ranitidine 300 82BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/17
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cers remained for at least half the patients (52%). In
contrast, by the end of the trial the ulcers were healed in
at least two-thirds of the patients receiving proton pump
inhibitors (67%).
As would be expected, when compared with placebo treat-
ment, the PPIs (lansoprazole and omeprazole) improved
the pooled healing RR at each time point. In relation to
ranitidine, the pooled healing RR of PPIs (lansoprazole,
omeprazole and pantoprazole) was also increased at both
four and eight weeks. There were no studies versus rabe-
prazole. The healing RR in each trial of the newer PPIs was
found to be comparable or better than omeprazole at each
time point (Figure 1).
Publication bias
The healing RR was plotted against sample size but there
was no trend with increasing size: small studies had heal-
ing RR similar to large studies with the same comparator
(Figure 2). There was one abstract [27] with data obtained
at 3 and 6 weeks, which is not included.
Discussion
In the absence of active treatment, the majority of patients
continued to have a gastric ulcer at the end of the trial. A
much higher healing rate was observed when patients re-
ceived treatment with a PPI when compared to either a
placebo or ranitidine. This is consistent with the results
obtained for treatment with PPIs when compared to rani-
tidine for both duodenal ulcers and gastro esophageal re-
flux disease [2,28]. We also found that, there is some
evidence of an advantage to prescribing two of the newer
PPIs (lansoprazole or pantoprazole) compared to ome-
prazole for gastric ulcer, since there was a 15% increase in
healing rates at 4 weeks. In addition, the newer PPIs (rab-
eprazole, lansoprazole and pantoprazole) have all been
show to produce superior improvement in clinical symp-
toms compared to omeprazole at both 2 and 4 weeks [24–
26].
Relatively few randomized controlled clinical trials have
been published on the efficacy of PPI for treating gastric
ulcers when compared with gastro esophageal reflux dis-
ease or with duodenal ulcers [29,30]. This could be due to
gastric ulcers being less frequently diagnosed than duode-
nal ulcer [31], or the importance of clinicians confirming
Table 2: Symptom improvement or resolution by study, time point and treatment group
Improvement (%Resolved)
Study Drug Comparator
Reference Symptom 2 wks 4 wks 2 wks 4 wks
Dekkers [26] Pain frequency 71 (34)1 82 (52)2 61 (29)1 65 (44)2
Day pain 88 (60)1 90 (75)2 75 (59)1 83 (67) 2
Night pain 82 (68)1 89 (84)2 79 (61)1 80 (68) 2
Witzel [25] Pain free 79 88 68 81
Florent [24] Daytime pain 863 603
Night pain 100 70
Bardhan [15] Pain free L30 = 75 65
L60 = 72
Michel [16] Epigastric pain relief 73 72
Valenzuela [13] Global assessment of GI symptoms O40 = 49.3
O20 = 40.5
Ital Coop Grp [19] Overall symptoms 75 87 65 80
Epigastric day pain 94 92
Epigastric night pain 96 91
Walan [20] Ulcer symptoms free O40 = 69 55
O20 = 62
Cloud [14] Frequency of symptoms Rab20=(64)2 (28)2
Rab40=(46)2
Severity of daytime symptoms Rab20=(62)2 (54)2
Rab40=(57)2
Severity of nighttime symptoms Rab20=(70)2 (65)2
Rab40=(55)2
w = week, Rab = rabeprazole, L = lansoprazole, O = omeprazole. The number after the letter indicates the dose. 1: three weeks, 2: six weeks, 3: 
eight weeks.BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/17
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Figure 1
Overall healing rate ratios and 95% CI of different proton pump inhibitors versus omeprazole or ranitidine
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a differential diagnosis between gastric ulcer and gastric
cancer. Some authors have also argued that the classifica-
tion of gastric and duodenal ulcers is artificial, since ulcers
could be driven distally or drawn proximally across the ar-
bitrary boundary of the pylorus [32]. Furthermore, some
clinical assessments may be complicated as 10–20% of
patients with gastric ulcers also have duodenal ulcers.
However, given the severity of the symptoms generally as-
sociated with a gastric ulcer, there no longer appears to be
a clear justification for continuing to conduct placebo-
controlled trials in these patients.
Recent observations have suggested that the duration of
treatment with acid secretory inhibitors is more important
than the degree of acid inhibition per 24-hours [33]. We
could not test the long-term effect of PPIs on ulcer relapse
rates, since there was not enough information published.
More research into maintenance therapy is clearly re-
quired, because the relative long-term efficacy of different
treatments, particularly the combination of PPIs with an-
tibiotics, and the effect of dose variation on the relapse
and complications from gastric ulcers is not well studied.
Other factors known to have an impact on gastric ulcer
healing are smoking; alcohol and ulcer size, but the pa-
pers did not report the healing results for these subgroups
of patients or by those variables. Unfortunately, the re-
searchers reported different clinical symptoms and meth-
ods to collect the data and so we could not pool these
results.
Conclusions
This study suggests that the first-line drug therapy for pa-
tients diagnosed with gastric ulcer should be a PPI, in pref-
erence to an H2 antagonist. This study indicated that
compared with ranitidine the PPIs provide faster onset of
action, greater relief of symptoms and increased healing
Figure 2
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rates. However, there is also clearly a need for additional
studies to determine the appropriate maintenance doses
and understand the factors influencing healing and re-
lapse rates.
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